 |
|
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis
Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park
Clin Mol Hepatol. 2022;28(2):254-264. Published online 2021 Dec 28 DOI: https://doi.org/10.3350/cmh.2021.0314
|
|
Citations to this article as recorded by
 Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
Pin‐Nan Cheng, I‐Cher Feng, Jyh‐Jou Chen, Hsing‐Tao Kuo, Pei‐Lun Lee, Ming‐Lung Yu, Yen‐Cheng Chiu, Hung‐Chih Chiu, Shih‐Chieh Chien, Pei‐Jer Chen, Chun‐Jen Liu
Alimentary Pharmacology & Therapeutics.2024; 59(2): 230. CrossRef Real‐world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B
Shuhei Hige, Kouji Aoki, Daisuke Nakamoto, John F. Flaherty, Irina Botros, Hajime Mizutani, Akinobu Ishizaki, Hiroki Konishi, Jason Yuan, Masahisa Jinushi, Leslie J. Ng
Journal of Viral Hepatitis.2024; 31(4): 165. CrossRef Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis
Kexin Tong, Mingjing Chen, Danni Wang, Haifeng Dai, Jiayi Peng, Jia Zhang, Jiao Zhou, Yujiao Chang, Wenxiang Huang
European Journal of Clinical Pharmacology.2024; 80(3): 335. CrossRef Reply to “Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in HBV patients”
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024;[Epub] CrossRef Application of Tenofovir Alafenamide Fumarate in Patients with Chronic Hepatitis B
雪 刘
Advances in Clinical Medicine.2024; 14(02): 3550. CrossRef The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis
Danqing Hu, Peng Wang, Xiaojing Wang, Xue Hu, Da Huang, Weiming Yan, Dong Xi, Meifang Han, Qin Ning, Hongwu Wang
Heliyon.2024; 10(7): e28653. CrossRef Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(2): 144. CrossRef Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
Hyeyeon Hong, Jonggi Choi
Clinical and Molecular Hepatology.2024; 30(2): 272. CrossRef Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients
Wenjuan Zhao, Yi Liu, Mengdi Zhang, Zixin Cui, Zhan Qu, Yiyang Li, Meijuan Wan, Wen Wang, Yunru Chen, Lei Shi, Jianzhou Li, Feng Ye
Frontiers in Medicine.2024;[Epub] CrossRef Efficacy comparison of high-genetic barrier nucleos(t)ide analogues in treatment-naïve chronic hepatitis B patients: a network meta-analysis
Jaejun Lee, Ahlim Lee, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Hyun Yang
The Korean Journal of Internal Medicine.2024; 39(4): 577. CrossRef Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B
Hyunjae Shin, Gyung Sun Lim, Jae Woong Yoon, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yuri Cho, Yun Bin Lee, Eun Ju Cho, Bo Hyun Kim, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Yoon Jun Kim
Journal of Medical Virology.2024;[Epub] CrossRef Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B
Fei Cao, Tao Fan, Xue Jiang, Jian Wang, Yilin Liu, Li Zhu, Ye Xiong, Shaoqiu Zhang, Zhiyi Zhang, Yifan Pan, Yuanyuan Li, Chao Jiang, Juan Xia, Xiaomin Yan, Jie Li, Xingxiang Liu, Chuanwu Zhu, Rui Huang, Chao Wu
Virology Journal.2024;[Epub] CrossRef Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta‐analysis
Jeong‐Ju Yoo, Eun Ae Jung, Sang Gyune Kim, Young Seok Kim, Min Jae Kim
Journal of the International AIDS Society.2024;[Epub] CrossRef Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment
Jiezuan Yang, Haifeng Lu, Baikun Chen, Lili Jiang, Hua Zhang, Ping Ye, Linfeng Jin, Lele Zhu
Journal of Immunology Research.2023; 2023: 1. CrossRef Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao
Heliyon.2023; 9(1): e13113. CrossRef Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial
Jonggi Choi, Young-Suk Lim, Ji-Hoon Kim, Kwan Soo Byun, Byung Chul Yoo
Clinical Gastroenterology and Hepatology.2023; 21(12): 3185. CrossRef Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation
Sihui Zhang, Chao Wang, Bei Liu, Qing-Bin Lu, Jia Shang, Yihua Zhou, Jidong Jia, Xiaoyuan Xu, Huiying Rao, Bingfeng Han, Tianshuo Zhao, Linyi Chen, Mingzhu Xie, Jiahao Cui, Juan Du, Jing zeng, Ninghua huang, Yaqiong Liu, Lei Zhang, Hui Zhuang, Fuqiang Cui
The Lancet Regional Health - Western Pacific.2023; 35: 100738. CrossRef Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
Eui Gwon Hwang, Eun-Ae Jung, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Hepatology International.2023; 17(4): 860. CrossRef Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis
Hui Liu, Cheng-Long Han, Bao-Wen Tian, Zi-Niu Ding, Ya-Fei Yang, Yun-Long Ma, Chun-Cheng Yang, Guang-Xiao Meng, Jun-Shuai Xue, Dong-Xu Wang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li
Expert Review of Gastroenterology & Hepatology.2023; 17(6): 623. CrossRef Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
Beom Kyung Kim, Sang Hoon Ahn
Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma
Peng Wang, Xinhui Wang, Xiaoli Liu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Lihua Yu, Xianbo Wang, Zhiyun Yang
BMC Cancer.2023;[Epub] CrossRef Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
Jonggi Choi, Won-Mook Choi, Young-Suk Lim
Clinics in Liver Disease.2023; 27(4): 809. CrossRef Comparisons of Insulin Resistance- and Steatosis-Based Scores in Monitoring Metabolic Associated Fatty Liver Disease Treatment Response
Junzhao Ye, Yansong Lin, Congxian Shao, Yanhong Sun, Shiting Feng, Bihui Zhong
Annals of Nutrition and Metabolism.2023; 79(5): 448. CrossRef Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Clinical and Molecular Hepatology.2023; 30(1): 49. CrossRef Incidence of Side Effects During Tenofovir Alafenamide Monotherapy in Patients with Chronic Hepatitis B
Fada Wang, Jing Zhou, Lanqing Li, Yujing Li, Yongfang Liu, Enqiang Chen
Diseases and Research.2023; 3(1): 11. CrossRef Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
Hung-Yao Lin, Tai-Chung Tseng
Clinical and Molecular Hepatology.2022; 28(2): 181. CrossRef Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B
Meng‐Lan Wang, En‐Qiang Chen
Alimentary Pharmacology & Therapeutics.2022; 56(6): 1090. CrossRef
|